Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

OBJECTIVE: To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). RESEARCH DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Linz, Peter E., Lovato, Laura C., Byington, Robert P., O’Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Force, Rex W., Crouse, John R., Ismail-Beigi, Faramarz, Simmons, Debra L., Papademetriou, Vasilios, Ginsberg, Henry N., Elam, Marshall B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2014
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931389/
https://www.ncbi.nlm.nih.gov/pubmed/24296848
http://dx.doi.org/10.2337/dc13-0790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931389/
https://www.ncbi.nlm.nih.gov/pubmed/24296848
http://dx.doi.org/10.2337/dc13-0790

Ejemplares similares